| Main Subject |
Hubs | Hubbers | Topics | Request |
| #1 in Business | Subscribe Email Print |
|
You are here: Home > Business > Management > Innovation Management - does the idea fit with the firm? |
|
Main Subject - Innovation Management - does the idea fit with the firm?
Creativity can be defined as problem identification and idea generation whilst innovation can be defi According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product ned as idea selection, development and commercialisation. There are distinct processes that enhance ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug. Examples of combination products may in problem identification and idea generation and, similarly, distinct processes that enhance idea selec lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together. tion, development and commercialisation. Whilst there is no sure fire route to commercial success, th here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe ese processes improve the probability that good ideas will be generated and selected and that investm d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations. Combination pro ent in developing and commercialising those ideas will not be wasted. One of the useful methods of v ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc aluing ideas is to analyse whether the firm, team or individual responsible for turning an idea into easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi commercial success has the required fit. Fit with the firm can be measured in a number of ways: a) nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically Does the idea have a strategic fit with the company? It may be a great idea but if lacks strategic f and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ it, its development and commercialisation may cause long term problems. In this case there are three ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi choices: drop it, license it or create a joint venture. b) Does the firm have the technical expertis ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it. Following aspects would a e to make it work? If not where can it be found? What is the cost of importing the technical expertis dd to the challenges in developing combination products: Which markets to tap where the combination products can do fairly well? Which combination prod e? c) Does the organisation have the business competencies to make it work? These include competenci cts are meaningful and rational? Which therapeutic categories to select? Which Combinations can address unmet needs of the patients? Do combin es in marketing, new product development, the ability to manage widely diverse and scattered employee tions increase the patient compliance? What would be the developing cost? How to tackle the risks encountered during combination product developmen and facilities. Again, is the idea big enough to justify the expense? These topics are covered in d t? As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel epth in the MBA dissertation on Managing Creativity & Innovation, which can be purchased (along with ping new procedures for reviewing their safety, efficacy and quality. Professional from academic institutions, pharmaceutical industries, health care indust a Creativity and Innovation DIY Audit, Good Idea Generator Software and Power Point Presentation) fro y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products m http://www.managing-creativity.com. You can also receive a regular, free newsletter by entering yo . As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de ur email address at this site. Kal Bishop, MBA ********************************** You are free to elopment. They need to be wiser in analyzing the market trends and the regulatory requirements. Companies that provide selfless information through particip reproduce this article as long as no changes are made and the author's name and site URL are retained tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
Related Articles:Defining Online Branding-Part 2 Change Management - Without the Problems Clone Your Successes by Planning your Succession
|